Cellular senescence in asthma: from pathogenesis to therapeutic challenges
R Wan, P Srikaram, V Guntupalli, C Hu, Q Chen… - …, 2023 - thelancet.com
Asthma is a heterogeneous chronic respiratory disease that impacts nearly 10% of the
population worldwide. While cellular senescence is a normal physiological process, the …
population worldwide. While cellular senescence is a normal physiological process, the …
The new biologic drugs: Which children with asthma should get what?
Novel biologics (targeted antibody therapies) have revolutionized the management of
severe childhood asthma. However, it is important that the right biologic is selected for the …
severe childhood asthma. However, it is important that the right biologic is selected for the …
Current and novel biologic therapies for patients with asthma and nasal polyps
HK Mandl, JE Miller, DM Beswick - Otolaryngologic Clinics of …, 2024 - oto.theclinics.com
Asthma and nasal polyps (NPs) are common diseases that often coexist and share
overlap** pathogenesis. Asthma affects nearly 300 million individuals worldwide and …
overlap** pathogenesis. Asthma affects nearly 300 million individuals worldwide and …
Effects of tezepelumab on quality of life of patients with moderate-to-severe, uncontrolled asthma: systematic review and meta-analysis
GCL Chagas, D Xavier, L Gomes, J Ferri-Guerra… - Current Allergy and …, 2023 - Springer
Abstract Purpose of Review To assess the effects of tezepelumab on quality of life (QoL) in
patients with moderate-to-severe, uncontrolled asthma. Recent Findings Tezepelumab …
patients with moderate-to-severe, uncontrolled asthma. Recent Findings Tezepelumab …
Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity
D Garg, LG Que, JL Ingram - Frontiers in Pharmacology, 2024 - frontiersin.org
Over 20 million adults and 6 million children in the United States (US) have asthma, a
chronic respiratory disease characterized by airway inflammation, bronchoconstriction, and …
chronic respiratory disease characterized by airway inflammation, bronchoconstriction, and …
Thymic Stromal Lymphopoietin (TSLP), Its Isoforms and the Interplay with the Epithelium in Allergy and Asthma
Thymic stromal lymphopoietin (TSLP) is a pleiotropic cytokine that has emerged as a critical
player in the development and progression of allergy and asthma. It is primarily produced by …
player in the development and progression of allergy and asthma. It is primarily produced by …
[HTML][HTML] Brazilian guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps‒2024 update
WT Anselmo-Lima, FR Romano, E Tamashiro… - Brazilian Journal of …, 2024 - Elsevier
Introduction Biologics targeting type 2 inflammation have revolutionized the way we treat
patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Particularly in severe …
patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Particularly in severe …
Immunogenicity of biologics used in the treatment of asthma
OAM Neunie, W Rabbani, D Baker… - Human …, 2024 - journals.sagepub.com
OBJECTIVE: Asthma is a major global disease affecting adults and children, which can lead
to hospitalization and death due to breathing difficulties. Although targeted monoclonal …
to hospitalization and death due to breathing difficulties. Although targeted monoclonal …
Clinical Trials and Outcomes in Anti-inflammatory Therapies
Inflammatory diseases represent a diverse group of disorders stemming from an overactive
immune response, affecting various organs and tissues and manifesting a spectrum of …
immune response, affecting various organs and tissues and manifesting a spectrum of …
Biologic Drugs for Severe Asthma
Background Asthma is a spectrum of chronic conditions that exhibit airway inflammation and
hyperreactivity. 1 Severe asthma affects approximately 5% to 10% of individuals living with …
hyperreactivity. 1 Severe asthma affects approximately 5% to 10% of individuals living with …